Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Progressive Multifocal Leukoencephalopathy.

Berger1

  • 1Department of Neurology, University of Kentucky College of Medicine, Kentucky Clinic L-445, Lexington, KY 40536-0284, USA. jrbneuro@pop.uky.edu

Current Treatment Options in Neurology
|November 30, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

True lupus found in a seven and a half year old girl.

Revue medicale de Nancy·2010
Same author

About a case of palmoplantar hyperhidrosis treated surgically, result dating from five years.

Memoires. Academie de chirurgie (France)·2010
Same author

Vaccine improves memory in "Alzheimer's" mice.

BMJ (Clinical research ed.)·2001
Same author

Study of B Decays to Charmonium States: B-->eta(c)K and B --> chi(c0)K.

Physical review letters·2001
Same author

Gut cells engineered to produce insulin

BMJ (Clinical research ed.)·2000
Same author

Statins could be useful in organ transplantation

BMJ (Clinical research ed.)·2000

Establishing a definitive diagnosis of progressive multifocal leukoencephalopathy (PML) is crucial. Improving immune status and discontinuing immunosuppression are key management strategies, with antiretroviral therapy beneficial for AIDS patients.

Area of Science:

  • Neuroimmunology
  • Viral Pathogenesis
  • Clinical Neurology

Background:

  • Progressive multifocal leukoencephalopathy (PML) is a rare, often fatal demyelinating disease.
  • PML is caused by the JC virus (JCV) in immunocompromised individuals.
  • Current treatment options for PML are limited and often ineffective.

Purpose of the Study:

  • To review the current understanding of PML diagnosis and management.
  • To evaluate the efficacy of various therapeutic strategies for PML.
  • To identify prognostic factors for survival in PML patients.

Main Methods:

  • Review of existing literature on PML diagnosis, treatment, and outcomes.
  • Analysis of clinical data and case reports.
  • Discussion of in vitro and in vivo studies of anti-JCV agents.

Related Experiment Videos

Main Results:

  • No therapy has proven effective in prospective trials; supportive care and immune reconstitution are primary.
  • Antiretroviral therapy (ART) prolongs survival in HIV-associated PML.
  • Cytosine arabinoside and other in vitro active agents have shown limited clinical success due to poor brain penetration or toxicity.

Conclusions:

  • Diagnosis must be unequivocal before experimental therapies.
  • Immune reconstitution is the cornerstone of PML management.
  • Further research and well-designed trials are needed to develop effective curative strategies for PML.